Industry
14.05.2021
Overall proportion of industry and non-industry income is: 86.4% industry income vs 13.6% non-industry income. Please find below a list of Industry Partners and related contributions for the financial year 2019:
Industry1 related income (2019)
Name of company/funder | Amount of income2 | Percentage of overall budget | |
Almirall | € 10,000 | 0,8% | |
Biogen | € 150,055 | 12,4% | |
Bristol-Myers-Squibb (BMS – formerly Celgene) | € 167,796 | 0,9% | |
Canopy Growth | € 11,310 | 13,6% | |
Icometrix | € 5,000 | 0,4% | |
MedDay | € 15,000 | 1,2% | |
Merck | € 159,710 | 13,2% | |
Mylan | € 30,000 | 2,5% | |
Novartis | € 241,222 | 19,9% | |
Quanterix | € 5,000 | 0,4% | |
Roche | € 117,000 | 9,7% | |
Sanofi-Genzyme | € 136,800 | 11,3% | |
Subtotal | € 1,211,105 | 86,4% |
[2] This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.
Code of Conduct
On a regular basis, EMSP also collaborates with the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Our approach is transparent and rules-based, as set out in our Code of Conduct.